Acrongenomics Inc.: Appointment of CEO
Monday August 6, 2007
VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Aug 6, 2007 -- Acrongenomics Inc. (OTCBB:AGNM) has appointed Dr. Dimitri Goundis as its Chief Executive Officer (CEO) effective as of September 3, 2007, bringing his important international experience in science, business and management to the company.
Dr. Goundis holds a Ph.D. in Biochemistry from the University of Oxford, a B.Sc. in Chemistry/Biochemistry from the University of London and a Certificate in Investment Management from the London Business School. From 1988 until 2006, he spent several years in the Pharmaceutical Industry, both in big Pharma (e.g. Hoffman La Roche) and in start-up companies, first The Medicines Company Inc., and then Speedel AG. He started at Hoffman La Roche in Research, then proceeded in Clinical Research, and later he was appointed as International Project Director leading multidisciplinary teams in drug development.
At The Medicines Company Inc., he was Senior Director for Project Management and following its successful IPO on Nasdaq in August 2000, he joined Speedel AG, a BioPharmaceutical company based in Basel, Switzerland. There he held several different positions of high responsibility, starting as Project Director, then Head of Project Management and finally Managing Director of Speedel Experimenta. Speedel AG was successfully listed on the Swiss Stock Exchange in September 2005.
"I am very happy with my appointment to lead Acrongenomics during its next stage of development; this is a company with a great opportunity to bring cutting edge science to the market," Dr. Goundis commented on his appointment at Acrongenomics.
"On behalf of the Board of Directors, I would like to take this opportunity to extent a warm welcome to Dr. Goundis to our company," said Plato Tzouvalis, President of Acrongenomics. "With his extended experience in both science and management and our successful dedicated team work we will take Acrongenomics one big step closer towards the commercialization of our novel and leading edge technology."
About Acrongenomics Inc.
Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
